Industry's Suits Against Medicare Price Negotiation: Consolidation And Expansion

As the date that the US Centers for Medicare and Medicaid Services (CMS) will publish the initial list of 10 drugs subject to the new Medicare price negotiation program approaches, the number of industry-backed lawsuits aiming to stop implementation continues to rise. Boehringer Ingelheim GmbH became the fifth individual manufacturer to file suit on 18 August, arguing in its case a need to protect its antidiabetic Jardiance from negotiation.

The first 10 drugs to face negotiations are expected to be announced by 1 September. There has been much speculation about which drugs could be targeted first, based on the cost to Medicare and brand longevity